Purpura is usually a medical emergency, and a thorough medical history and physical examination is usually adequate. Other tests may be warranted if the clinical history or exam is not suggestive of a specific cause. Thrombocytopenic purpura is more common in men, and tends to be due to underlying leukemia or blood disease. This condition is associated with significant morbidity and expense. The authors believe that this article better descriptions the features of purpura and thrombocytopenic purpura than other articles.
We suggest that these diseases should be treated with steroids, particularly in the young. Steroids are an efficacious and safe first-line treatment for purpura, thrombocytopenic, idiopathic and other causes of thrombocytopenia in childhood. It may be necessary to consider a more extended approach to treat purpura, thrombocytopenic, idiopathic, in children. Appropriate dosage as well as the duration of therapy should be monitored.
Purpura, thrombocytopenic, idiopathic often do not respond to a particular therapy. This is especially true in adults. Physicians may recommend a trial of corticosteroids and anticoagulants. The goal of therapy is the control of symptoms and possible reversal of underlying causes. Some physicians will administer corticosteroids and others, anticoagulants. It is important that practitioners are informed of the current medical literature for their particular situation as it may influence the choice of therapies most likely to be effective.
Purpura thrombocytopenic, idiopathic refers to unexplained thrombocytopenia thrombocytopenic, idiopathic purpura that is a manifestation of a non-septic condition and may occur in association with immune-mediated disorders, autoimmune states, and malignancies as well as septic and idiopathic forms. Purpura should be considered in all cases of thrombocytopenia, thrombocytopenic purpura, and unexplained thrombocytopenic purpura when there is a diagnosis of sepsis.
Purpura, thrombocytopenic, idiopathic occurs in about 1 in 1000 adults in the United States. No clinical trials were published on this condition; this study only examined one condition of a group of conditions termed idiopathic thrombocytopenic purpura (ITP). This disorder's management is based on the experience gathered through personal experience and published peer review articles.
These patients may have systemic disease as part of a multisystem disorder, but none of the patients with purpura, thrombocytopenic, idiopathic had any identifiable infection. These patients may have systemic disease as part of a multisystem disorder, but few of them had identifiable infection. The purpura, thrombocytopenic, idiopathic syndrome apparently affects a variety or unrelated systems, such as the immune system, the skin and blood vessels, or the brain, with no relationship with infections.
For people with mild to moderate thrombocytopenia when antiplatelets are deemed inappropriate, there is only a 16% risk of myocardial infarction, a 4% chance of developing a fatal stroke, and the probability of death is no higher than for the general population. For people with symptomatic thrombocytopenia a significant increase (p = 0.002) in rate of fatal and non-fatal heart attacks was observed. Thus, the prescribing of antiplatelet therapy for uncomplicated, mild to moderate thrombocytopenia should be viewed as a reasonable option for the prevention of a myocardial infarction or stroke with minimal bleeding risk.
This is the first study that shows that purpura, thrombocytopenic, idiopathic may be a syndrome that runs in families. Familial thrombocytopenia warrants clinical exploration in future families in an attempt to define the genetic susceptibility to this disease and unravel its epidemiology.
We provide insights into the causes of this rare form of purpura, which can often result in morbidity, especially when the hemorrhages cause anemia, an immune complexes disease, or vasculitis. These conditions are seen in a variety of underlying diseases, including systemic lupus erythematosus, cryoglobulinemia, polyarteritis enteritis, mixed connective tissue disease, systemic sclerosis, and antiphospholipid syndrome. These diagnoses need to be considered when a patient with purpura is being evaluated.
The evidence from this case study and pooled analysis [and other case studies and retrospective case-controls studies] suggests that this treatment was effective in improving the patient's condition. More prospective studies on the treatment of thrombocytopaenic purpura are currently needed.
The most common and major side effect is aplastic anemia (6%; 2/29 in the placebo group and 4/41 patients in the dexamethasone group). Other frequent side effects were a sore throat (26%; 5/29), bronchodilation medication use (6%; 2/29), fever (6%; 2/29), arthralgia (13%; 3/29), abdominal pain and diarrhea (10%; 3/29), chest pain (3%; 1/29), elevated C-reactive protein (2%; 1/29), and arthralgia (5%; 1/29). There was only one major adverse event of a headache (1%; 1/41).
purpura, thrombocytopenic, idiopathic is a disease that affects people of all ages and is of variable duration. Patients will often have many medical problems that complicate or make their treatment more difficult. Purpura, thrombocytopenic, idiopathic is highly variable in its presentation. There is an excellent correlation between disease duration and treatment outcome.